TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Oncology
Cervical cancer in pregnancy
Key Statistics
- 0.1–12.0 — Incidence per 10,000 pregnancies
- ≤22 wks — Cut-off for staging lymphadenectomy
- 14–35 wks — Chemotherapy safe window
Don't-miss facts
-
Cervical cancer = commonest gynae malignancy in pregnancy; incidence 0.1–12.0/10,000 pregnancies
-
MRI first-line staging (safe, any gestation); CT second-line only, minimise fetal radiation
-
Diathermy loop biopsy in pregnancy: ~25% haemorrhage risk – theatre/clinic with haemorrhage facilities only
-
Staging PLND not after 22 weeks; sentinel node biopsy not recommended in pregnancy
-
Chemotherapy: contraindicated 1st trimester; safe 14–35 weeks; carboplatin + paclitaxel; 3-week gap before delivery
-
BGCS 2020: simple trachelectomy discouraged in pregnancy; antenatal trachelectomy → 20–30% preterm birth
-
Breastfeeding contraindicated during chemo; wait ≥14 days post last cycle
-
Only melanoma, haematopoietic and lung cancers metastasise to placenta/fetus
Evidence-tier at a glance
MRI safe any gestation · carboplatin+paclitaxel preferred
Avoid: 1st-trimester chemo · sentinel node biopsy · PLND >22wk · trachelectomy (BGCS)
Abbreviation Key
- INCIP — International Network on Cancer, Infertility and Pregnancy
- LSCS — lower segment caesarean section
- FIGO — International Federation of Gynaecology and Obstetrics
- MDT — multidisciplinary team
- MRI — magnetic resonance imaging
- BGCS — British Gynaecological Cancer Society
- CT — computed tomography
- CIN — cervical intraepithelial neoplasia
- LVSI — lymphovascular space invasion
- CGIN — cervical glandular intraepithelial neoplasia
- PLND — pelvic lymph node dissection
- TOC — test-of-cure
- SLN — sentinel lymph node
- HRT — hormone replacement therapy
- NACT — neoadjuvant chemotherapy
- NICE — National Institute for Health and Care Excellence
- LLETZ — large loop excision of the transformation zone
- AC — adjuvant chemotherapy
Source: Howe T et al. Cervical cancer in pregnancy: diagnosis, staging and treatment. The Obstetrician & Gynaecologist 2022;24:31–39. doi:10.1111/tog.12783
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).